Zerlasiran for the Treatment of Atherosclerotic Cardiovascular Disease
To the Editor A recent article1 reported that zerlasiran was well tolerated, with a time-averaged percent change in lipoprotein(a) concentration of more than 80% from baseline to 36 weeks in patients with atherosclerotic cardiovascular disease. However, we have some concerns about this study.
Authors
- Jiahao Meng (ORCID: https://orcid.org/0000-0003-0511-3365)
- Shuguang Gao (ORCID: https://orcid.org/0000-0003-1135-7876)
- Yumei Wu
Institutions
- Central South University (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- JAMA
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1001/jama.2025.0031
- Citations
- 1
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 1.29